Global GM2 Gangliosidosis Market, By Type (Infantile, Juvenile and Adult), By Therapeutics (Enzymatic augmentation, Bone marrow transplantation, Enzyme enhancement and Substrate reduction therapy), By Drugs (Anticonvulsant, Antipsychotic medication and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI472721 | Publish Date: July 2021 | No. of Pages: 130

Global GM2 Gangliosidosis Market Companies

  • Pfizer, Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • Novartis AG
  • Recursion Pharmaceuticals, Inc.
  • IntraBio Inc.
  • Johnson & Johnson Services, Inc.
  • Axovant Sciences, Inc.

Recent News:

  • According to PubMed Central research article, The GM2 gangliosidoses, Tay-Sachs (TSD), Sandhoff disease (SD) and GM2 activator deficiency are rare, progressive, neurodegenerative lysosomal storage disorders (LSDs) that are uniformly fatal and without effective therapy.